These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 36042588)

  • 21. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
    Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
    Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low dose of ROSuvastatin in combination with EZEtimibe effectively and permanently reduce low density lipoprotein cholesterol concentration independently of timing of administration (ROSEZE): A randomized, crossover study - preliminary results.
    Obońska K; Kasprzak M; Tymosiak K; Fabiszak T; Krintus M; Kubica J
    Cardiol J; 2021; 28(1):58-66. PubMed ID: 33200812
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rosuvastatin increased serum osteocalcin levels independent of its serum cholesterol-lowering effect in patients with type 2 diabetes and hypercholesterolemia.
    Kanazawa I; Yamaguchi T; Yamauchi M; Sugimoto T
    Intern Med; 2009; 48(21):1869-73. PubMed ID: 19881236
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination Therapy of Ezetimibe and Rosuvastatin for Dyslipidemia: Current Insights.
    Chilbert MR; VanDuyn D; Salah S; Clark CM; Ma Q
    Drug Des Devel Ther; 2022; 16():2177-2186. PubMed ID: 35832642
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy evaluation of PCSK9 monoclonal antibody (Evolocumab) in combination with Rosuvastatin and Ezetimibe on cholesterol levels in patients with coronary heart disease (CHD): A retrospective analysis from a single center in China.
    Liu Y; Han B
    Transpl Immunol; 2022 Apr; 71():101444. PubMed ID: 34375677
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of Ezetimibe Alone or in Addition to a Statin on Plasma PCSK9 Concentrations in Patients with Type 2 Diabetes and Hypercholesterolemia: A Pilot Study.
    Miyoshi T; Nakamura K; Doi M; Ito H
    Am J Cardiovasc Drugs; 2015 Jun; 15(3):213-9. PubMed ID: 25896669
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patient and physician factors influence decision-making in hypercholesterolemia: a questionnaire-based survey.
    Krempf M; Simpson RJ; Ramey DR; Brudi P; Giezek H; Tomassini JE; Lee R; Farnier M
    Lipids Health Dis; 2015 May; 14():45. PubMed ID: 25985907
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome.
    Simons L; Tonkon M; Masana L; Maccubbin D; Shah A; Lee M; Gumbiner B
    Curr Med Res Opin; 2004 Sep; 20(9):1437-45. PubMed ID: 15383192
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared to rosuvastatin 10 mg in high-risk patients with and without type 2 diabetes mellitus inadequately controlled despite prior statin monotherapy.
    Vaverkova H; Farnier M; Averna M; Missault L; Viigimaa M; Dong Q; Shah A; Johnson-Levonas AO; Brudi P
    Cardiovasc Ther; 2012 Apr; 30(2):61-74. PubMed ID: 20626402
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Moderate-Intensity Rosuvastatin/Ezetimibe Combination versus Quadruple-Dose Rosuvastatin Monotherapy: A Meta-Analysis and Systemic Review.
    Kang Y; Park JM; Lee SH
    Yonsei Med J; 2024 Jan; 65(1):19-26. PubMed ID: 38154476
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination Therapy of Rosuvastatin and Ezetimibe in Patients with High Cardiovascular Risk.
    Yang YJ; Lee SH; Kim BS; Cho YK; Cho HJ; Cho KI; Kim SY; Ryu JK; Cho JM; Park JI; Park JS; Park CG; Chun WJ; Kim MA; Jin DK; Lee N; Kim BJ; Koh KK; Suh J; Lee SH; Lee BK; Oh SJ; Jin HY; Ahn Y; Lee SG; Bae JH; Park WJ; Lee SC; Lee HC; Lee J; Park C; Lee B; Jang Y
    Clin Ther; 2017 Jan; 39(1):107-117. PubMed ID: 28007331
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.
    Foody JM; Toth PP; Tomassini JE; Sajjan S; Ramey DR; Neff D; Tershakovec AM; Hu H; Tunceli K
    Vasc Health Risk Manag; 2013; 9():719-27. PubMed ID: 24265554
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients.
    Catapano AL; Davidson MH; Ballantyne CM; Brady WE; Gazzara RA; Tomassini JE; Tershakovec AM
    Curr Med Res Opin; 2006 Oct; 22(10):2041-53. PubMed ID: 17022864
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial.
    Goldberg AC; Sapre A; Liu J; Capece R; Mitchel YB;
    Mayo Clin Proc; 2004 May; 79(5):620-9. PubMed ID: 15132403
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of combination therapy with ezetimibe and statins versus a double dose of statin monotherapy in participants with hypercholesterolemia: a meta-analysis of literature.
    Yu M; Liang C; Kong Q; Wang Y; Li M
    Lipids Health Dis; 2020 Jan; 19(1):1. PubMed ID: 31900179
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study.
    Ballantyne CM; Hoogeveen RC; Raya JL; Cain VA; Palmer MK; Karlson BW;
    Atherosclerosis; 2014 Jan; 232(1):86-93. PubMed ID: 24401221
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of Switching From High-Efficacy Lipid-Lowering Therapies to Generic Simvastatin on LDL-C Levels and LDL-C Goal Attainment Among High-Risk Primary and Secondary Prevention Populations in the United Kingdom.
    Cao X; Ejzykowicz F; Ramey DR; Sajjan S; Ambegaonkar BM; Mavros P; Tunceli K
    Clin Ther; 2015 Apr; 37(4):804-15. PubMed ID: 25626487
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis.
    Ambegaonkar BM; Tipping D; Polis AB; Tomassini JE; Tershakovec AM
    Atherosclerosis; 2014 Dec; 237(2):829-37. PubMed ID: 25463129
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect on Fasting Serum Glucose Levels of Adding Ezetimibe to Statins in Patients With Nondiabetic Hypercholesterolemia.
    Toth PP; Catapano AL; Farnier M; Foody J; Tomassini JE; Jensen E; Polis AB; Hanson ME; Musliner TA; Tershakovec AM
    Am J Cardiol; 2016 Dec; 118(12):1812-1820. PubMed ID: 27756478
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low-density lipoprotein cholesterol reduction and target achievement after switching from statin monotherapy to statin/ezetimibe combination therapy: Real-world evidence.
    Lee J; Lee SH; Kim H; Lee SH; Cho JH; Lee H; Yim HW; Yoon KH; Kim HS; Kim JH
    J Clin Pharm Ther; 2021 Feb; 46(1):134-142. PubMed ID: 33026659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.